{"id":"drug-na-831","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"NA-831 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin. By reducing glucose reabsorption, NA-831 helps to improve glycemic control in patients with type 2 diabetes.","oneSentence":"NA-831 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:35:28.596Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04452565","phase":"PHASE2, PHASE3","title":"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection","status":"UNKNOWN","sponsor":"Biomed Industries, Inc.","startDate":"2022-06-15","conditions":"Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2","enrollment":525},{"nctId":"NCT04540185","phase":"PHASE3","title":"A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19","status":"UNKNOWN","sponsor":"Biomed Industries, Inc.","startDate":"2020-11-01","conditions":"Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection","enrollment":3600},{"nctId":"NCT04480333","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831","status":"UNKNOWN","sponsor":"Biomed Industries, Inc.","startDate":"2020-09-15","conditions":"Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Drug: NA-831","genericName":"Drug: NA-831","companyName":"Biomed Industries, Inc.","companyId":"biomed-industries-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NA-831 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}